NEW YORK, March 17, 2014 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased The Medicines Company ("Medicines" or the "Company") (Nasdaq:MDCO) securities between February 20, 2013 and February 12, 2014.
For more information, click here: http://zlk.9nl.com/the-medicines-company-mdco.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information including but not limited to the following: (a) that Medicine's drug candidate Cangrelor did not show superiority to clopidogrel, a competing drug already approved by the Food and Drug Administration, and (b) that Medicine's CHAMPION clinical trials were unethically and inappropriately administered.
On February 12, 2014, the Food and Drug Administration voted against approval of Cangrelor for patients undergoing certain cardiovascular procedures.
If you suffered a loss in Medicines you have until April 22, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/the-medicines-company-mdco.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.